Naturalistic, self-assignment comparative trial of bupropion SR, a nicotine patch, or both for smoking cessation treatment in primary care.
The effectiveness of bupropion SR, a nicotine patch, or both, when co-administered with cognitive-behavioral therapy, on smoking cessation was evaluated under treatment-as-usual conditions in a primary care smoking cessation clinic. Consecutive consenting patients (n = 189) assigned themselves to one of three treatments according to personal preference: nicotine patch (NTP; n = 27), bupropion SR (B; n = 101), and bupropion SR plus nicotine patch (B + NTP; n = 61). Six-month self-reported abstinence rates were 14.8%, 27.7%, and 34.4%, respectively. Odds ratios for 6-month abstinence, with NTP as reference, were 2.2 (CI = 0.7-5.9; p = .19) for B, and 3.0 (CI = 0.9-9.9; p = .07) for B + NTP. Resemblance of abstinence pattern and magnitude between this naturalistic study and randomized clinical trials of bupropion SR may support tentative inferences of stability and generalizability of clinical trial efficacy findings.
Gold
Paul B
PB
Department of Veterans Affairs Medical Center, Charleston, SC, USA. goldpb@musc.edu
Rubey
Robert N
RN
Harvey
Richard T
RT
D000279:Administration, Cutaneous; D000368:Aged; D016642:Bupropion / Q000627:therapeutic use*; D015928:Cognitive Behavioral Therapy / Q000379:methods; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009538:Nicotine / Q000008:administration & dosage*; D018722:Nicotinic Agonists / Q000008:administration & dosage*; D011320:Primary Health Care; D016540:Smoking Cessation / Q000379:methods*; D014029:Tobacco Use Disorder / Q000188:drug therapy / Q000628:therapy*; D016896:Treatment Outcome
D018722:Nicotinic Agonists; D016642:Bupropion; D009538:Nicotine